Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29903895.
- Also identified by DOI 10.1158/1078-0432.CCR-18-1311.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor burden is a key consideration for the treatment of solid malignancies. Large baseline tumor size (an assessment of volume of disease in target lesions prior to treatment), elevated lactate dehydrogenase (LDH), and site of disease are prognostic of poor overall survival (OS) for patients with advanced melanoma treated with pembrolizumab. <i>Clin Cancer Res; 24(20); 4915-7. ©2018 AACR</i> <i>See related article by Joseph et al., p. 4960</i>.
Medical subject headings
- Melanoma
- Skin Neoplasms